Efficacy and safety of tanezumab monotherapy or combined with non-steroidal anti-inflammatory drugs in the treatment of knee or hip osteoarthritis pain

Annals of the Rheumatic Diseases

Volumn 74, Issue 6, 2015, Pages 1202-1211

  Schnitzer, Thomas J ^a   Ekman, Evan F ^b   Spierings, Egilius L H ^c   Greenberg, H Scott ^d   Smith, Michael D ^d   Brown, Mark T ^d   West, Christine R ^d   Verburg, Kenneth M ^d   Kvien, Tore K ^e  

^a NORTHWESTERN UNIVERSITY   (United States)

^b Appalachian Regional Orthopaedic and Sports Medicine   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d PFIZER INC   (United States)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CREATINE KINASE; NAPROXEN; PLACEBO; TANEZUMAB; MONOCLONAL ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT; PYRAZOLE DERIVATIVE; SULFONAMIDE;

ADULT; ANEMIA; ARTHRALGIA; ARTICLE; ATRIAL FIBRILLATION; BACKACHE; BURNING SENSATION; CARDIOPULMONARY ARREST; CARPAL TUNNEL SYNDROME; CHOLELITHIASIS; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FALLING; FEMALE; FEMUR FRACTURE; HEADACHE; HIP OSTEOARTHRITIS; HUMAN; HYPERTENSION; HYPESTHESIA; INCIDENCE; INFLUENZA; JOINT SWELLING; KNEE OSTEOARTHRITIS; LABORATORY TEST; LUNG CANCER; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; MUSCLE SPASM; MUSCULOSKELETAL PAIN; NEUROLOGIC EXAMINATION; NONHODGKIN LYMPHOMA; OSTEOARTHRITIS; PAIN ASSESSMENT; PANCREAS CANCER; PARESTHESIA; PATIENT GLOBAL ASSESSMENT; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SENSORY DYSFUNCTION; SINUSITIS; SPINE FRACTURE; STOMACH CANCER; THORAX PAIN; TIBIA FRACTURE; UPPER GASTROINTESTINAL BLEEDING; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VITAL SIGN; WESTERN ONTARIO AND MCMASTER UNIVERSITIES OSTEOARTHRITIS INDEX; AGED; ARTHROPLASTY; CHEMICALLY INDUCED; CLINICAL TRIAL; COMPLICATION; DRUG COMBINATION; EDEMA; MIDDLE AGED; OSTEOARTHRITIS, HIP; OSTEOARTHRITIS, KNEE; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ARTHRALGIA; ARTHROPLASTY, REPLACEMENT; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; EDEMA; FEMALE; HUMANS; HYPESTHESIA; MALE; MIDDLE AGED; NAPROXEN; OSTEOARTHRITIS, HIP; OSTEOARTHRITIS, KNEE; PARESTHESIA; PYRAZOLES; SULFONAMIDES; TREATMENT OUTCOME;

EID: 84935029062     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2013-204905     Document Type: Article

References (24)

1. Abdiche YN, Malashock DS, Pons J. Probing the binding mechanism and affinity of tanezumab, a recombinant humanized anti-NGF monoclonal antibody, using a repertoire of biosensors. Protein Sci 2008; 17:1326-35.
2. Hefti FF, Rosenthal A, Walicke P.A., et al. Novel class of pain drugs based on antagonism of NGF. Trends Pharmacol Sci 2006; 27:85-91.
3. Brown M, Murphy F, Radin D., et al. Tanezumab reduces osteoarthritic hip pain: Results of a randomized, double-blind, placebo-controlled phase 3 trial. Arthritis Rheum 2013; 65:1795-803.
4. Brown MT, Murphy FT, Radin D.M., et al. Tanezumab Reduces Osteoarthritic Knee Pain: Results of a Randomized, Double-Blind, Placebo-Controlled Phase III Trial. J Pain 2012; 13:790-8.
5. Ekman EF, Gimbel JS, Bello A.E., et al. Efficacy and Safety of Intravenous Tanezumab in Osteoarthritis Hip and Knee Pain: Comparison to Placebo and Naproxen in Two Phase III Studies (NCT00830063 & NCT00863304). Presented at: The American Pain Society (APS) 30th Annual Scientific Meeting; Austin, TX, 19-21 May 2011.
6. Evans RJ, Moldwin RM, Cossons N, et al. Proof of concept trial of tanezumab for the treatment of symptoms associated with interstitial cystitis. J Urol 2011; 185:1716-21.
7. Katz N, Borenstein DG, Birbara C, et al. Efficacy and safety of tanezumab in the treatment of chronic low back pain. Pain 2011; 152:2248-58.
8. Lane NE, Schnitzer TJ, Birbara C.A., et al. Tanezumab for treatment of knee osteoarthritis pain. N Engl J Med 2010; 363:1521-31.
9. Nagashima H, Suzuki M, Araki S., et al. Preliminary assessment of the safety and efficacy of tanezumab in Japanese patients with moderate to severe osteoarthritis of the knee: a randomized, double-blind, dose-escalation, placebo-controlled study. Osteoarthritis Cartilage 2011; 19:1405-12.
10. Schnitzer TJ, Lane NE, Birbara C, et al. Long-term open-label study of tanezumab for moderate to severe osteoarthritic knee pain. Osteoarthritis Cartilage 2011; 19:639-46.
11. Balanescu AR, Feist E, Wolfram G., et al. Efficacy and safety of tanezumab added on to diclofenac sustained release in patients with knee or hip osteoarthritis: a double-blind, placebo-controlled, parallel-group, multicentre phase III randomised clinical trial. Ann Rheum Dis 2014; 73:1665-72.
12. Altman R, Asch E, Bloch D., et al. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Arthritis Rheum 1986; 29:1039-49.
13. Kellgren JH, Lawrence JS. Radiological assessment of osteo-arthrosis. Ann Rheum Dis 1957; 16:494-502.
14. Bellamy N, Buchanan WW, Goldsmith C.H., et al. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheum 1988; 15:1833-40.
15. Stengaard-Pedersen K, Ekesbo R, Karvonen A.L., et al. Celecoxib 200 mg q.d. is efficacious in the management of osteoarthritis of the knee or hip regardless of the time of dosing. Rheumatology (Oxford) 2004; 43:592-5.
16. Pham T, van der Heijde D, Altman RD, et al. OMERACT-OARSI initiative: Osteoarthritis Research Society International set of responder criteria for osteoarthritis clinical trials revisited. Osteoarthritis Cartilage 2004; 12:389-99.
17. Apfel SC, Schwartz S, Adornato B.T., et al. Efficacy and safety of recombinant human nerve growth factor in patients with diabetic polyneuropathy: A randomized controlled trial. rhNGF Clinical Investigator Group. JAMA 2000; 284:2215-21.
18. Dyck PJ, Litchy WJ, Lehman K.A., et al. Variables influencing neuropathic endpoints: the Rochester Diabetic Neuropathy Study of Healthy Subjects. Neurology 1995; 45:1115-21.
19. Pfizer Inc. Tanezumab arthritis advisory committee briefing document. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ArthritisDrugsAdvisoryCommittee/UCM295205.pdf (accessed 8 Mar 2014).
20. Hochberg MC, Abramson SB, Hungerford D.S., et al. Adjudication of reported serious adverse joint events in the tanezumab clinical development program. Arthritis Rheum 2012; 64:S113.
21. Mantyh PW, Koltzenburg M, Mendell L.M., et al. Antagonism of nerve growth factor-TrkA signaling and the relief of pain. Anesthesiology 2011; 115:189-204.
22. Zorbas M, Hurst S, Shelton D., et al. A multiple-dose toxicity study of tanezumab in cynomolgus monkeys. Regul Toxicol Pharmacol 2011; 59:334-42.
23. Food and Drug Administration Center for Drug Evaluation and Research. Background Materials. Meeting of the Arthritis Advisory Committee (AAC). http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ArthritisDrugsAdvisoryCommittee/UCM295202.pdf (accessed 8 Mar 2014).
24. Food and Drug Administration Center for Drug Evaluation and Research. Background Materials Addendum. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ArthritisDrugsAdvisoryCommittee/UCM295203.pdf (accessed 8 Mar 2014).